Skip to main content
GPLB
OTC Life Sciences

Annual Report Highlights Severe Going Concern Risk, No Operations, and Full Reliance on Related Party Funding

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$0.017
Mkt Cap
$342.11K
52W Low
$0
52W High
$2.6
Market data snapshot near publication time

summarizeSummary

The annual report confirms Green Planet Bio Engineering is a non-operating shell company facing severe going concern risks, relying solely on a related party for funding, and lacking a public trading market.


check_boxKey Events

  • Substantial Doubt About Going Concern

    Both management and the independent auditors have issued a 'going concern' warning, citing no current business activity, recurring losses, and dependence on external financing and continued related party support.

  • Non-Operating Shell Company Status

    The company remains a public reorganized shell corporation with no active business operations or operating revenues for the years ended December 31, 2025, and 2024.

  • Full Reliance on Related Party Funding

    All cash flow needs for 2025 were provided solely by a related party, Global Funds Holdings Corp., to which the company owes $484,678 as of December 31, 2025. The CEO/CFO is also a director of this related party.

  • No Trading Market for Common Stock

    The filing explicitly states there is currently no trading market for the company's common stock, limiting liquidity for stockholders and subjecting it to 'penny stock' regulations if a market develops.


auto_awesomeAnalysis

This annual 10-K filing reveals that Green Planet Bio Engineering Co. Ltd. continues to operate as a public shell corporation with no active business operations or revenue. Both management and the independent auditors have issued a 'going concern' warning, indicating substantial doubt about the company's ability to continue operations without additional financing. The company is entirely dependent on a related party for funding its administrative expenses, with liabilities to this party increasing significantly. The absence of a trading market for its common stock further exacerbates the risk, making it highly illiquid and speculative.

At the time of this filing, GPLB was trading at $0.02 on OTC in the Life Sciences sector, with a market capitalization of approximately $342.1K. The 52-week trading range was $0.00 to $2.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed GPLB - Latest Insights

GPLB
Mar 31, 2026, 4:10 PM EDT
Filing Type: 10-K
Importance Score:
9